<DOC>
	<DOCNO>NCT00846196</DOCNO>
	<brief_summary>Randomized , double-blind , 2-treatment , 2-period , 2-sequence , crossover study , The study consist screen visit , study center admission ( precede Treatment Periods 1 2 ) , 2 treatment period ( 4 day ) , 1 washout period ( 14 17 day separate period 1 2 ) , exit procedure .</brief_summary>
	<brief_title>A Study Assess Bioequivalence Different Formulations Risedronate Healthy Male Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>male female , 18 65 year age female , nonlactating either surgically sterile postmenopausal body mass index less equal 32 kg/m2 screening use bisphosphonate within 1 month history GI disease use medication within 714 day prior schedule dosing day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>